GEN Exclusives

More »

GEN News Highlights

More »
Nov 8, 2007

CombinatoRx Heads Up Research to Identify Treatments for DMD

  • CombinatoRx inked an agreement with Charley’s Fund and the Nash Avery Foundation to support Duchenne muscular dystrophy (DMD) research.

    CombinatoRx will get up to $3 million in research funding. The firm will also own all intellectual property generated from the collaboration and worldwide commercialization rights to all candidates.

    CombinatorRx’ cHTS™ drug discovery technology will be used to identify disease modifying, multitargeted treatments. The company will screen for synergistic activity in both DMD-relevant in vitro assays and those assays that have implicated mechanisms beyond DMD.

    “We are excited about the possibility of developing new medicines built from synergistic combinations of approved drugs,” says Benjamin Seckler, M.D., president of Charley’s Fund, a foundation that finances therapeutics for DMD. “This unique approach to drug development could significantly compress the timeline for getting new therapies into the clinic.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?